Use our development programs at a very early stage by entering into a long-term strategic partnership

Kinase inhibitor development programs Technology Partnership


License technologies, drug candidates and radiotracers from Oncodesign’s portfolio

Kinase inhibitors in oncology, CNS and inflammation Technologies



The power and selectivity of Nanocyclix® molecules applied to the entire kinome. Learn More


Oncodesign News

Business Continuity Plan – COVID-19

Oncodesign ensures business continuity during the COVID-19 pandemic

Learn more

[Congress] 14th WRIB – !NEW DATES! 22 – 26 June – Phoenix Arizona – USA

Our expert and DMPK laboratory manager, Dr. Mouhssin Oufir will be present and happy to meet you!

Learn more

[Congress] EMIM !NEW DATES! 25-28 August 2020 – Thessaloniki – Greece

It takes 2 to tango: compound labeling and complementary imaging approaches to show how your compound works & targets the right patient.  

Learn more

Word from the Chairman

Since our April 2014 IPO, we have accelerated our development and have become an international biopharma company specialized in precision medicine pursuing ambitious development objectives underpinned by acquisition-led growth and investments in innovative therapeutic research programs.

Learn More



Oncodesign’s mission is to discover innovative new therapies effective against cancer and serious illnesses with unmet medical needs.

Oncodesign has opted to take the time to build up all the dimensions of its organization—scientific, technical, business, starting with the most crucial one, the human dimension.

Our values Job offers/work-study arrangements Internship available Spontaneous applications

Contact Us

Invalid Input

Invalid Input

Invalid Input

Please write a subject for your message.

Please let us know your message.

Invalid Input

Sales team

If you have any questions, please contact the member of our sales team responsible for your geographical region, and we will get back to you as swiftly as we can.

Oncodesign sales team

Connect with us now